Nousq Pte Ltd. has been declared the winner of the 2022 Asia Pacific Accelerator program with its pediatric ear tube insertion device. Singapore-based Nousq’s victory was determined by a live audience vote on during the Medtech Innovator Asia Pacific 2022 Grand Finals, organized by medical device accelerator Medtech Innovator and the Asia Pacific Medical Technology Association (APACMed).
Aim Biotech Pte. Ltd. has launched a lab tool that can closely model human disease. The organic system can add vascularization and immune competence to organoids, spheroids and tumor biopsies. This allows for the creation of a more defined and tunable microenvironment that more closely emulates the complexity of human physiology.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies.
Singapore’s Agency for Science, Technology and Research (A*STAR) has inked a deal with Boehringer Ingelheim GmbH to develop and commercialize targeted cancer therapies.
Singapore’s Health Sciences Authority (HSA) recently updated its guidelines for software as medical devices (SaMDs) to broaden its scope on a number of related matters. The new guidelines were finalized after an industry input period when the HSA collected feedback until the middle of August 2021. It marks the second revision of HSA guidelines on SaMDs, the first revision was meted out in April 2020.
